STEAP2 and prostate carcinoma: However, the expression levels of STEAP2 in the tumor tissues of lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate cancer (PRAD), stomach cancer (STAD) (p < 0.001), pheochromocytoma and paraganglioma (PCPG) (p < 0.01), head and neck squamous cell carcinoma (HNSC), liver hepatocellular carcinoma (LIHC), and pancreatic adenocarcinoma (PAAD) (p < 0.05) were higher than those in the corresponding control tissues.